Poehling Capital Management INC. Has $938,000 Holdings in Pfizer Inc. $PFE

Poehling Capital Management INC. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 36.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 37,672 shares of the biopharmaceutical company’s stock after selling 21,767 shares during the period. Poehling Capital Management INC.’s holdings in Pfizer were worth $938,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after buying an additional 7,031,162 shares during the period. State Street Corp raised its holdings in Pfizer by 0.9% during the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after buying an additional 2,786,098 shares during the period. Northern Trust Corp increased its holdings in shares of Pfizer by 1.4% in the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after purchasing an additional 869,175 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Pfizer by 1.9% in the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after purchasing an additional 897,786 shares during the period. Finally, Legal & General Group Plc increased its holdings in shares of Pfizer by 8.6% in the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock valued at $1,063,565,000 after purchasing an additional 3,296,415 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. CICC Research assumed coverage on Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. HSBC upped their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Finally, Royal Bank Of Canada reiterated an “underperform” rating and issued a $25.00 target price on shares of Pfizer in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.84.

Pfizer Trading Up 1.3%

Shares of NYSE PFE opened at $25.66 on Wednesday. The stock has a market cap of $146.27 billion, a price-to-earnings ratio of 19.59 and a beta of 0.35. The business has a 50 day simple moving average of $26.93 and a 200 day simple moving average of $26.21. Pfizer Inc. has a 52 week low of $22.81 and a 52 week high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s payout ratio is presently 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a new Phase 3 endometrial cancer trial, signaling continued investment in its oncology pipeline and a potential long-term growth driver. Pfizer Takes Aim at Merck in New Phase 3 Endometrial Cancer Trial
• Positive Sentiment: Several recent opinion pieces argued that Pfizer still looks undervalued, which may be supporting bargain-hunting interest in the stock. Why Pfizer Stock Still Looks Deeply Undervalued In 2026
• Positive Sentiment: Technical commentary noted Pfizer’s RSI moved above 50, which traders often read as a sign of improving momentum. Tata Motors PV among 6 stocks showing bullish RSI upswing
• Neutral Sentiment: Analyst coverage remained unchanged at “Hold,” suggesting the market still sees Pfizer as fairly valued despite recent catalysts. Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of “Hold” from Analysts
• Negative Sentiment: Pfizer and other big drugmakers came under pressure after reports that the TrumpRx drug-pricing initiative may be set for “dramatic expansion,” reviving policy overhang concerns for the sector. PFE, NVO, LLY: Pharma Stocks Drop on News TrumpRx Set for ‘Dramatic Expansion’

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.